---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116703"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:46:35.589039+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Apogee Q3 net loss $20.8M; cash $422.9M; APG777 Phase 1 dosed ahead of schedule

## Summary
- Net loss $20.8M in Q3 2023 vs $19.7M in Q3 2022; R&D spend rose to $17.1M from $9.9M.
- Cash $422.9M as of Sept 30, 2023; expected runway into Q4 2026 after $345M IPO in July.
- Phase 1 trial of APG777 begun ahead of schedule; initial PK/safety data from healthy volunteers expected mid-2024.
- Development candidate for APG808 (anti-IL-4Rα) finalized in Q4 2023; preclinical half-life up to 26 days vs 12 days for DUPIXENT.
- Mark C. McKenna appointed Chairman; Matt Batters joined as General Counsel in August 2023.

## SEC filing metadata
- accession: 0001104659-23-116703
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465923116703/0001104659-23-116703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465923116703/tm2330055d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116703
- JSON: https://secwatch.observer/filing/0001104659-23-116703.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116703.txt

## Key facts
- Earnings Releases
  Apogee Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1974640/000110465923116703/0001104659-23-116703-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.